Joseph Loscalzo, a director at Ionis Pharmaceuticals Inc. (NASDAQ: IONS), has completed the sale of approximately $5.8 million worth of common stock. The transactions took place on May 4, 2026, and were carried out under a Rule 10b5-1 trading plan that had been put in place on November 18, 2025.
The total volume of shares sold amounted to 77,289. These transactions were split into two distinct sales events. The first portion of the sale involved 59,508 shares, which were traded at prices ranging from $74.49 to $75.49, resulting in a weighted average price of $74.9024 per share. The second portion consisted of 17,781 shares, sold at prices between $75.495 and $75.98, which yielded a weighted average price of $75.5826 per share.
Prior to executing these sales on May 4, 2026, Mr. Loscalzo had acquired the same number of shares - 77,289 - through the exercise of non-qualified stock options. The cost for these acquisitions, which occurred on the same day as the sales, ranged from an exercise price of $38.06 to $64.80 per share, totaling roughly $3.77 million. After accounting for both the option exercises and the subsequent sales, Mr. Loscalzo's direct ownership in Ionis Pharmaceuticals stands at 36,330 shares.
The timing of this insider activity occurs against a backdrop of substantial stock price growth; Ionis has seen its share price increase by 136% over the previous year, with current trading levels noted at $76.85. Notably, some analysis suggests that the stock may currently be overvalued based on Fair Value calculations.
This insider movement follows a strong first-quarter 2026 earnings report from Ionis Pharmaceuticals. The company's financial results for the quarter exceeded market expectations, posting an earnings per share of -$0.56, which was more favorable than the anticipated -$0.85. Additionally, revenue reached $246 million, surpassing the projected $199.24 million. In light of these figures, Ionis Pharmaceuticals has upwardly revised its full-year 2026 total revenue guidance to a range of $875 million to $900 million, up from the earlier estimate of $800 million to $825 million.
Market analysts have responded to these financial developments with varying adjustments. Oppenheimer has maintained an Outperform rating while raising its price target for IONS to $110. Stifel also adjusted its outlook, increasing its price target from $83 to $86 while retaining a Hold rating. The company is currently navigating preparations for potential approval within the larger sHTG patient population, a factor that has influenced revenue forecasts and pricing strategies. While Ionis expects a temporary decline in second-quarter revenue due to pricing adjustments, it anticipates growth in the latter half of the year following the launch of sHTG.